Clinical Trial

Use of Allogeneic Extracellular Secretomes (EV)Derived From Umbilical Cord Mesenchymal Stromal Cells: a Phase I Open-label Safety Trial.

Study acronym: EVVitiCTC

Active, Not Recruiting Phase 1

Record status

This record was last updated April 30, 2025 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.

Summary

Aim of the study: The primary endpoint of this work is to explore the safety of allogeneic extracellular secretomes "extracellular vesicles" (EV) derived from umbilical cord mesenchymal cells (HUCMSCs) when injected perilesional repeatedly in stable non-facial vitiligo. Methods: Adults with stable non-facial vitiligo for more than three months not exceeding 300 mm 2 were included in the study. A total of 13 patients of either gender, were given perilesional EV weekly for 3 weeks. Adverse events were regularly monitored for six months. The re-pigmentation was assessed at 3 and 6 months The non-injected areas are used as control for comparison of repigmentation. The injected skin area and the control areas were photographed at baseline, at the end of treatment, and at three, and six months.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-02-03.

Trial Details

NCT Number	NCT06813027
Lead Sponsor	University of Jordan Collaborators: Abdalla Awidi Abbadi, MD
Conditions	Vitiligo
Enrollment	13 participants
Start Date	2023-01-01
Primary Completion	2026-01-30 (estimated)
Study Completion	2027-01-30 (estimated)
Updated on ClinicalTrials.gov	2025-04-30